Sugi Predict

Sugi Predict / Compounds / 4-Nitrophenyl Methylcarbamate

4-Nitrophenyl Methylcarbamate

4-Nitrophenyl Methylcarbamate

SCHEMBL3337757

CNC(=O)Oc1ccc([N+](=O)[O-])cc1

nearest known ligand 0.61

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ MGLL Q99685 2/20 0.61
▸ GAA P10253 3/20 0.60
▸ BCL9 O00512 1/20 0.57
▸ CTNNB1 P35222 1/20 0.57
▸ KMT2A Q03164 4/20 0.51
▸ PKM P14618 1/20 0.51
▸ ALDH1A1 P00352 5/20 0.51
▸ SMN1; SMN2 Q16637 3/20 0.51
▸ MAPT P10636 4/20 0.50
▸ NPC1 O15118 2/20 0.50
▸ RAB9A P51151 2/20 0.50
▸ MEN1 O00255 2/20 0.50
▸ MAPK1 P28482 1/20 0.50
▸ NPSR1 Q6W5P4 1/20 0.50
▸ MYOC Q99972 1/20 0.50
▸ RECQL P46063 1/20 0.48
▸ HSD17B10 Q99714 1/20 0.48
▸ HTT P42858 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
4-Nitrophenyl Methylcarbamate SCHEMBL31417181 0.88 MGLL (0.57) MGLLGAABCL9CTNNB1KMT2A
SCHEMBL11409993 0.87 MGLL (0.56) MGLLGAABCL9CTNNB1KMT2A
SCHEMBL16588595 0.85 MGLL (0.60) MGLLGAABCL9CTNNB1KMT2A
SCHEMBL17373926 0.85 MGLL (0.60) MGLLGAABCL9CTNNB1KMT2A
SCHEMBL3762920 0.84 MGLL (0.59) MGLLGAABCL9CTNNB1KMT2A
SCHEMBL2147924 0.83 MGLL (0.58) MGLLGAABCL9CTNNB1KMT2A
SCHEMBL12893245 0.82 ALDH1A1 (0.51) GAAKMT2AALDH1A1SMN1; SMN2MAPT
SCHEMBL15775217 0.82 MGLL (0.57) MGLLGAABCL9CTNNB1KMT2A
SCHEMBL2499123 0.82 MGLL (0.57) MGLLGAABCL9CTNNB1KMT2A
SCHEMBL13137639 0.82 MGLL (0.57) MGLLGAABCL9CTNNB1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116999396-A Modular compositions for removal of soluble biomolecules and related methods 纳米提克斯有限责任公司 2023-11-07 — — CN disclosed
CN-112759545-B 3- (dimethylamino methyl) piperidine-4-alcohol derivative and preparation method and pharmaceutical application thereof 复旦大学 2022-12-13 — — CN disclosed
CN-115260211-A Thiophene fused ring containing derivative, pharmaceutical composition, preparation method and application thereof 长春金赛药业有限责任公司 2022-11-01 — — CN disclosed
WO-2022053010-A1 FUSED RING PYRIMIDONE DERIVATIVES FOR USE IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES Janssen Sciences Ireland Unlimited Company (IE) 2022-03-17 — — WO disclosed
CN-114146056-A Modular compositions for scavenging soluble biomolecules and methods related thereto 纳米提克斯有限责任公司 2022-03-08 — — CN disclosed
US-11028052-B2 Compounds useful as modulators of TRPM8 FIRMENICH INCORPORATED (US) 2021-06-08 — — US disclosed
CN-112759545-A 3- (dimethylamino methyl) piperidine-4-alcohol derivative and preparation method and pharmaceutical application thereof 复旦大学 2021-05-07 — — CN disclosed
EP-3461816-B1 FIVE-MEMBERED HETEROCYLIC COMPOUNDS USEFUL AS MODULATORS OF TRPM8 FIRMENICH INCORPORATED (US) 2021-03-24 — — EP disclosed
US-10745364-B2 Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease LYCERA CORPORATION (US) 2020-08-18 — — US disclosed
US-20190292159-A1 TETRAHYDRONAPHTHYRIDINE, BENZOXAZINE, AZA-BENZOXAZINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE MERCK SHARP & DOHME LLC 2019-09-26 — — US disclosed
EP-0820455-A1 5H, 10H-IMIDAZO [1,2-a]INDENO [1,2-e]PYRAZIN-4-ONE DERIVATIVES, PREPARATION THEREOF, AND DRUGS CONTAINING SAID DERIVATIVES Aventis Pharma S.A. (FR) 1998-01-28 — — EP disclosed
WO-1997010246-A1 INDENO[1,2-e]PYRAZIN-4-ONES, PREPARATION THEREOF AND MEDICAMENTS CONTAINING SAME RHONE-POULENC RORER S.A. (FR) 1997-03-20 — — WO disclosed
EP-0752991-A1 INDENO[1,2-e]PYRAZINE-4-ONES, PREPARATION THEREOF AND DRUGS CONTAINING SAME Aventis Pharma S.A. (FR) 1997-01-15 — — EP disclosed
EP-0745673-A2 Catalytic antibody regulated prodrug therapy ZENECA LIMITED (GB) 1996-12-04 — — EP disclosed
WO-1996031511-A1 5H,10H-IMIDAZO[1,2-a]INDENO[1,2-e]PYRAZIN-4-ONE DERIVATIVES, PREPARATION THEREOF, AND DRUGS CONTAINING SAID DERIVATIVES RHONE-POULENC RORER S.A. (FR) 1996-10-10 — — WO disclosed
WO-1995026349-A1 INDENO[1,2-e]PYRAZINE-4-ONES, PREPARATION THEREOF AND DRUGS CONTAINING SAME RHONE-POULENC RORER S.A. (FR) 1995-10-05 — — WO disclosed
EP-0158074-B1 MICROBIOCIDE BAYER AG (DE) 1989-06-28 — — EP disclosed
US-4683233-A FUNGICIDES, BACTERICIDES BAYER AKTIENGESELLSCHAFT (DE) 1987-07-28 — — US disclosed
EP-0158074-A1 Microbiocide BAYER AG (DE) 1985-10-16 — — EP disclosed
US-3938986-A ISOPROPYL N-PHENYLCARBAMATE OR ISOPROPYL N-(3-CHLOROPHENYL)CARBAMATE AND 4-CHLOROPHENYL N-METHYLCARBAMATE PPG INDUSTRIES, INC. (US) 1976-02-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10745364-B2 Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease RORB, RORA, RORC MGLL 4868/4885GAA 1111/4885BCL9 1571/4885
US-11028052-B2 Compounds useful as modulators of TRPM8 TRPM8, TRPM7, TRPA1 MGLL 939/4885GAA 3493/4885BCL9 4574/4885
US-20190292159-A1 TETRAHYDRONAPHTHYRIDINE, BENZOXAZINE, AZA-BENZOXAZINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE RORB, RORA, RORC MGLL 4868/4885GAA 1111/4885BCL9 1571/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.